Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once ...

Biogen’s salanersen has shown promise in slowing neuronal damage and opening new motor milestones, according to interim ...

Biogen's early-stage spinal muscular atrophy drug salanersen showed safety, motor improvements and 70% reduction in ...

Panelists discuss how spinal muscular atrophy is an autosomal recessive genetic disease affecting motor neurons with 3 ...

Panelists discuss how spinal muscular atrophy (SMA) treatment will evolve over the next 5 years, likely incorporating ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared positive topline results from the ...

Antisense-based therapy salanersen (BIIB115/ION306) is a possible follow-up to Biogen's big-selling Spinraza (nusinersen) therapy for SMA, which has come under pressure from increased competition in ...

Biogen has pointed to an early readout from a small phase 1 trial as evidence that its antisense oligonucleotide salanersen ...

Children suffering from Spinal Muscular Atrophy (SMA) – a rare but debilitating genetic condition – are being denied a simple ...

Based on these encouraging Phase 1 data, Biogen (NASDAQ:BIIB) is engaging with regulators to advance its investigational ...

BiogenBIIB said Wednesday its experimental treatment helped children with a devastating muscle-wasting disease even after they received an approved gene therapy from NovartisNVS.The company already ...